The FDA decision date for efanesoctocog alfa, an investigational factor VIII therapy, is set for February 28, 2023 Priority review based on pivotal data from the XTEND-1 Phase 3 study… Read More
Date: 07 Sep 2022 Time: 3:30pm – 6:30pm PDT VANTEC OPEN NETWORK Featuring short 90-second pitches from local entrepreneurs – some of whose promising ventures are backed by local accelerators and incubators. We… Read More
Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death 80% of Patients Achieved Guideline Directed LDL-C Levels of <55 mg/dL at Week 12… Read More
Longer-term survival results underscoring role of KEYTRUDA® (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189) Seven-year survival from SOLO-1 and final overall survival (OS) results from… Read More
Analyses highlight long-term efficacy and safety results, including real-world data, from studies of SKYRIZI® (risankizumab) in moderate to severe psoriasis and active psoriatic arthritis Presentations include data from the largest-of-its-kind study that… Read More
